Principal Investigators

Dr. Eyad Elkord

Eyad Elkord

 Principal Investigator (QBRI, Qatar)
 Associate Professor (HBKU, Qatar)
 Honorary Professor (University of Manchester, UK)
Dr Eyad Elkord has different positions as Principal Investigator at Qatar Biomedical Research Institute, and an Associate Professor at Hamad Bin Khalifa University, Qatar; an Honorary Professor at the Institute of Cancer Sciences-University of Manchester, UK; and an Honorary Senior Lecturer at University of Salford, UK. He received his BSc in 1995 from Al-Quds University (Jerusalem), MPhil in 2001 from Bergen University (Norway) and PhD in Tumor Immunology in 2005 from University of Wales College of Medicine, Cardiff University (UK). He was a Postdoctoral Scientist (Jan 2005-Dec 2007) in the laboratory of Prof. Peter Stern at the Paterson Institute for Cancer Research, University of Manchester (UK), and was promoted to a Research Fellow/Group Leader of the Clinical Immunotherapy Laboratory at the University of Manchester (Jan 2008-Nov 2010). He then undertook a Lecturer position with the School of Environment & Life Sciences, University of Salford (Dec 2010-July 2012), and was promoted in 2012 to Senior Lecturer. He moved to the College of Medicine & Health Sciences-United Arab Emirates University in 2012 and was an Associate Professor of Immunology until September 2016. Dr Elkord is a member of scientific societies, including British Society for Immunology, European Academy of Allergology and Clinical Immunology, Immunology Interest Group (National Institutes of Health) and European Macrophage and Dendritic Cell Society. He is the recipient of UAE University Award for Excellence in Scholarship in 2016, and the Dean's annual research prize, College of Science & Technology, University of Salford, UK in 2012. He is an awardee of a certificate of achievement for publishing in top journals and bringing recognition to UAE University in 2013, 2014 and 2015. Dr Elkord is an editorial board member for peer-reviewed international journals including BMC Cancer and Journal of Immunology Research. He is ad hoc reviewer to many international journals and well-known grant bodies including Medical Research Council, Wellcome Trust, Yorkshire Cancer Research, Leukaemia Lymphoma Research and Qatar Foundation. Dr Elkord’s research in the area of T regulatory cells is well recognised, and he has edited an eBook for Frontiers in Immunology in 2013. He is a contributing author to “The Halifax Project” task force focused on “A Broad-Spectrum Integrative Design for Cancer Prevention and Therapy”. He has presented his work in different national and international meetings and conferences. Dr Elkord has more than 55 publications in peer reviewed high-impact international journals with more than 2400 citations and an h-index of 24.
Dr Elkord’s research interest focuses on Cancer Immunology and Immunotherapy and the use of different immunotherapeutic modalities for treating cancer. Additionally, his group is interested in investigating mechanisms employed by tumors to evade immune-mediated destruction with special focus on the role and function of immunosuppressive cells [T regulatory cells (Tregs) and myeloid-derived suppressor cells (MDSCs)].
  • Cellular and molecular profiling of different immune cell subsets in the tumor microenvironment and circulation of cancer patients;
  • Molecular and epigenetic profiling of breast and colorectal tumors;
  • Investigating the role of immune checkpoints in T cells as potential therapeutic targets;
  • Epigenetic modifications behind the upregulation of immune checkpoints in breast and colorectal tumor microenvironment;
  • Role of STAT signaling pathways in the upregulation of PD-L1 in breast cancer;
  • Role and function of Tregs and MDSCs in cancer;
  • Investigation of Tregs and MDSCs in Type 1 Diabetes Mellitus;
  • Interaction and mechanisms utilized by tumors to induce and/or expand Tregs;
  • Investigating the cellular immunity to human tumor-associated antigens and discovering MHC class I and II epitopes derived from these antigens;
  • Identification and isolation of tumor-specific T effector cells and investigating potential strategies for improving antitumor-specific immune responses.
Sasidharan Nair V, Toor SM, Ali BR, Elkord E. Dual inhibition of STAT1 and STAT3 activation downregulates expression of PD-L1 in human breast cancer cells. IExpert Opin Ther Targets. 2018 Apr 27. doi: 10.1080/14728222.2018.1471137. [Epub ahead of print]

Sasidharan Nair V & Elkord E. Immune checkpoint inhibitors in cancer therapy: A Focus on T regulatory cells. Immunol Cell Biol. 2018 Jan;96(1):21-33.

Syed Khaja AS, Toor SM, El Salhat H, Ali BR, Faour I, ulHaq N, Elkord E. Preferential Accumulation of Regulatory T cells with Highly Immunosuppressive Characteristics in Breast Tumor Microenvironment. Oncotarget. 2017 May 16;8(20):33159-33171.

Syed Khaja AS, Toor SM, El Salhat H, Ali BR, Elkord E. Intratumoral FoxP3+Helios+ Regulatory T Cells Upregulating Immunosuppressive Molecules Are Expanded in Human Colorectal Cancer. Front Immunol. 2017;8:619.

Toor SM, Syed Khaja AS, El Salhat H, Faour I, Kanbar J, Quadri AA, Albashir M, Elkord E. Myeloid cells in circulation and tumor microenvironment of breast cancer patients. Cancer Immunol Immunother. 2017 Jun;66(6):753-764.

Chaudhary B, Elkord E. Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting. Vaccines (Basel). 2016 Aug 6;4(3). pii: E28.

Complete list of Publications
Collaborator Name Institute Research Area
Dr. M. Abu Nada Hamad Medical Corporaton, Doha, Qatar Cancer Immunology
Dr. M. Abdul Ghani Hamad Medical Corporaton, Doha, Qatar Diabetes Mellitus
Prof. Peter L Stern Paterson Institute for Cancer Research, Manchester, UK Cancer Immunology
Prof. Bassam Ali United Arab Emirates University, UAE Transcriptome analysis
Institution Course Name Role
HBKU (2016-present) Cancer Immunology & Immunotherapy (Postgraduate) Coordinator & Lecturer
UAEU (2013-2016) Basic Principles of Microbiology Immunology (undergraduate) Lecturer
UAEU (2014-2016) Infection, Inflammation and Immunity (undergraduate) Lecturer
UAEU (2012-2016) Principles of Cellular & Molecular Immunology (postgraduate) Lecturer
UAEU (2013-2015) Immune-Mediated Diseases (postgraduate) Coordinator & Lecturer
University of Salford (2010-2012) Clinical Immunology Lecturer

Name Institution Time
Dr. Pramod Darvin QBRI/HBKU 2018-Present
Areej Mesleh HBKU 2018-Present
Asma Elashi HBKU 2018-Present
Dr. Varun Sasidharan Nair QBRI/HBKU 2017-Present
Salman M Toor QBRI/HBKU 2014-Present
Hibah Shaath QBRI/HBKU 2017-Present
Rowaida Taha QBRI/HBKU 2016-Present
Dr. Azharuddin Khaja UAE University 2015-2017
Shereena Lootah UAE University 2013-2019
May Abd al Samid University of Salford 2013-2016
Yazan Khaled University of Manchester 2011-2013
Belal Chaudhary University of Salford 2012-2014
Debbie Burt University of Manchester 2006-2010

Institution Committee
Hamad Bin Khalifa University Member of postgraduate admission committee
QBRI Member of the Internal Grant Program committee
QBRI Member of the recruitment committee
Hamad Bin Khalifa University Coordinator of Cancer Immunology & Immunotherapy module
UAE University Research grant committee
University of Salford Research ethics committee
University of Salford Research committee
Back to Top